VBI announces progress on synthetic vaccine development
The biopharmaceutical company offered results from a testing phase of VBI-1501A, a potential CMV vaccine. The product is currently being manufactured in amounts needed for research. VBI's Senior Vice President of Research, Dr. David E. Anderson, described the production scale as a key component for proceeding towards approval and clinical trials.
"We believe this positive interim data validates our eVLP vaccine platform and its potential utility in creating novel vaccine candidates for CMV and other indications," Anderson said.
The company’s eVLP vaccine platform will hopefully enable a new class of vaccines designed to resemble viruses structurally without containing infectious material. VBI intends to start formal toxicology studies in the second quarter of 2015.
During recent testing, VBI utilized electron microscopy to confirm the integrity of the eVLP particles used to create the potential vaccine product.
CMV is a leading cause of prenatal developmental delays.
VBI develops technologies to expand vaccine protection in underserved markets. The company is based in Cambridge, Massachusetts, and operates research facilities in Ottawa, Ontario.